Remyelination: From Molecular Mechanism to Therapy
Special Issue Editor
Interests: oligodendroglia differentiation; remyelination; multiple sclerosis; neurodegeneration; intracellular traffic; yeast
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear colleagues,
Primary demyelination is observed in several pathologies of the central nervous system. Among the primary ones are Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Acute Disseminated Encephalomyelitis (ADEM), Progressive Multifocal Leukoencephalopathy (PML), Leukodystrophies (e.g., Metachromatic Leukodystrophy, Krabbe disease, Adrenoleukodystrophy), and Guillain-Barré Syndrome (GBS), which also affects the peripheral nervous system.
An unmet goal for these diseases is to identify a remyelination therapy that could restore at least partially the white matter defects. Recently, it has been shown that even an incomplete remyelination resulting from a pharmacologically improved oligodendrogenesis can restore visual cortical function in mice (Della Flora Nunes et al., 2025 Nature Communication 16:732), suggesting that a better understanding of the molecular mechanism of demyelination and of how promyelinating drugs can stimulate oligodendroglia differentiation can help to develop more effective compounds, if we understand the window of intervention. In this Special Issue, we would like to focus on the attempts to shed light on the molecular bases of demyelination, as well as reports collecting data and/or describing novel attempts to remyelinate therapies
Guest Editor
Dr. Antonella Ragnini-Wilson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- demyelination
- oligodendroglia differentiation
- regenerative therapies
- myelin disease
- neurodegeneration
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
